Navigation Links
Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
Date:11/12/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Nov. 12 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced positive final results from its pilot GHRH Phase II study. Within only 4 weeks of treatment, Akela GHRH induced a highly significant stimulation of endogenous growth hormone (GH) secretion and a marked increase of circulating insulin-like growth factor (IGF-1) as compared to placebo in patients with chronic kidney disease. These endocrine effects were associated with a significant increase in Fat Free Mass (FFM), and concomitant reduction in Fat Mass (FM) when measured by DEXA scan and bioelectrical impedance (BIA). As we reported in July 2007, the study did not reveal significant changes between treatment groups in total body protein turnover. Total body protein turnover, as measured by 13C leucine kinetics, was normal in both treatment groups already at baseline, most probably reflecting adaptative changes of metabolic balance in the chronic disease state.

ABOUT THE STUDY:

The study was conducted at 3 European sites. It was designed to evaluate the clinical potential of GHRH analogue (AKL-0707) administration in improving body composition, nutritional and metabolic parameters in malnourished patients with stage IV or pre-dialytic stage V chronic kidney disease (CKD). Malnutrition was defined by either serum albumin <40 g/l, body mass index (BMI) <23, or a greater than 5% loss of body weight in the last 6 months.

Twenty-eight patients were randomized to either GHRH analogue subcutaneously (sc.) (13 patients) or placebo sc. (15 patients). Twenty-six subjects completed the study as planned. The mean age was 61.8 and 63.4 in the GHRH analogue and placebo groups, respectively. The treatment was administered twice daily (AM & PM) for
'/>"/>

SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Akela Pharma reports results for third quarter of fiscal 2007
5. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Dry eyes, contrary to popular opinion, are not ... have pointed out, today’s technology has practically enabled younger and ... result of using laptops and smartphones to go about ... this phenomenon, it has become imperative for people of today ... from having dry eyes, but prevent it from ever happening ...
(Date:7/14/2014)... Sometimes, thinking “inside the box” can be ... first product release, Joyboxx™ - The world’s only hygienic ... , Inventor and CEO, Deborah Semer began designing a ... solution for their ‘toys’ after she realized no such ... , Semer met 30-year industry veteran Phyllis Heppenstall, the ...
(Date:7/14/2014)... NATURALLY, DANNY SEO, a new magazine from ... a Fall issue that hits newsstands nationwide on July ... healthy, natural and good for you life with a ... travel, home, and entertaining all through Danny’s unique point-of-view ... of gimmicky weight loss tips and fluffy celebrity profiles, ...
(Date:7/14/2014)... July 14, 2014 The Cabin Chiang ... its new Alumni Community website – a ... to help them maintain lifelong recovery wherever they live ... providing clients the tools to help them maintain their ... essential part of any reputable treatment programme. As a ...
(Date:7/14/2014)... new analysis has found that rates of testicular cancer ... Hispanic American men, but not among their non-Hispanic counterparts. ... journal of the American Cancer Society, the findings indicate ... of testicular cancer in Hispanic adolescents and young adults, ... cause of this trend. , Testicular cancer is one ...
Breaking Medicine News(10 mins):Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 2Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 2Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 4Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 6Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Testicular cancer rates are on the rise in young Hispanic Americans 2
... research published in The Lancet states that, consuming a ... faster information processing and memory in the older adults. ... reduced levels of folate, and elevated levels of amino ... restricts cognitive ability, increasing the risk of dementia. ...
... the NHS trust to cater to mental problems afflicting the ... a document enabled by Durham County Council's inquiry committee, recognized ... in Durham and Darlington. The report threw light on the ... problems across six primary care trust areas in the region. ...
... the sake of good health., Students of Pittsburgh’s Plum ... last 10 months; via cafeteria meals. This was announced Thursday. ... by-products such as hulls of oats, soybeans, peas and rice, ... school meals to cut down calories while preserving a favorable ...
... showed reasonable resistance to Tamiflu, an antiviral, in two Egyptians who ... the medical community. ,The report also states that the ... in 2005. The occurrence of this strain in Egypt reveals that ... Tamiflu by the birdflu virus has not changed the WHO stance ...
... for short-term relief of chronic back pain, but their ... by researchers at Yale School of Medicine, who also ... in 24 percent of cases. ,“Patients with ... medications are used despite the concerns clinicians have with ...
... molecule that is part of a complex signaling network ... periventricular heterotopia (PVH), a congenital brain malformation, Yale School ... often leads to a variety of neurological disorders such ... It has many environmental and genetic causes, but is ...
Cached Medicine News:Health News:Long-Term Narcotics Use for Back Pain May Be Ineffective and Lead to Abuse 2Health News:Missing Molecule Has Important Role in a Developmental Brain Abnormality 2
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
(Date:7/10/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... a quarterly dividend of $0.275 (27.5 cents) per share on ... 1, 2014, to holders of record on July 21, 2014. ... is dedicated to helping people on their path to better ... the United States . Through the company,s more than ...
(Date:1/15/2014)... SAN ANTONIO , Jan. 15, 2014 Most ... take, according to a recent online survey* sponsored by ... among the National Osteoporosis Foundation online support community, ... to take medication that comes in a form other ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Inc. (OTCBB: PLCSF), a company focused on innovative medical ... REMEDIAL II investigator-sponsored clinical trial of RenalGuard® ... , a peer-reviewed journal of the American Heart Association ... in the September 2011 issue of the publication.  The ...
... A national analysis conducted by Sperling,s BestPlaces and ... Columbus, Ohio, as one of the nation,s Hypertension ... factors and complications. The identification of the Hypertension ... hypertension awareness program called Commit to Control ...
Cached Medicine Technology:REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 2REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 3REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation 4Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 2Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 3Columbus Included in Analysis of Top Hypertension Hot Spots in the United States 4
Sterile Silicone Oil for Intraocular Application....
Alcon offers medical grade perfluoropropane (SF6) intraocular gases for ophthalmological use....
Silikon 1000 (purified polydimethylsiloxane) is a highly purified long chain polydimethylsiloxane trimethylsiloxy terminated silicone oil. For use as a postoperative retinal tamponade during vitreore...
Round knurled handle, overall length 130 mm....
Medicine Products: